Boston Scientific announces results for third quarter 2026

MARLBOROUGH, Mass., Oct. 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operational1 and organic2 basis, all compared to the prior year period.

PRNewsWire • Oct 28, 2026

Heartflow to Report Third Quarter 2026 Financial Results on November 12, 2026

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2026 after market close on Thursday, November 12, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2026.

GlobeNewsWire • Oct 19, 2026

HeartFlow's CEO Sells 38,900 Shares for $1.8 Million After the Stock Hit a 52-Week High

The transaction involved 38,900 shares valued at ~$1.8 million based on a weighted average price of $46.78 per share. The executive traded shares equal to 11% of the equity stake held before the filing.

The Motley Fool • Sep 15, 2026

HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High

The sale of 33,416 shares generated a total value of approximately $1.7 million based on a weighted average execution price of $49.85. The traded shares represent 13% of the equity stake held by the officer before the transaction.

The Motley Fool • Sep 6, 2026

Baron SMID Cap ETF Q2 2026 Portfolio Activity

During the quarter, we initiated a position in Advanced Drainage Systems, the leading U.S. manufacturer of stormwater and onsite wastewater management products. We view Axon Enterprise as a market leading "atoms plus electrons" software provider with huge competitive moats. We sold the HeartFlow position in the quarter as we grew incrementally more concerned with the presence of competitors on the market.

Seeking Alpha • Sep 4, 2026

Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half

FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate Use Criteria for cath lab referrals FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate Use Criteria for cath lab referrals

GlobeNewsWire • Aug 28, 2026

Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference

SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Wells Fargo 21st Annual Healthcare Conference. The fireside chat, which will include a slideshow presentation followed by a question-and-answer session, will take place in Boston on Wednesday, September 9, 2026, at 3:45 p.m. ET / 12:45 p.m. PT.

GlobeNewsWire • Aug 27, 2026

HeartFlow's Chief Medical Officer Sells 9,219 Shares Amid a Soaring Stock Price. What Does That Mean for Investors?

The executive sold 9,219 shares at $41.23 per share on August 17, 2026, generating ~$380,100. The transaction reduced the insider's direct equity position by 10%, while total beneficial ownership decreased by 4%.

The Motley Fool • Aug 20, 2026

HeartFlow: An Impressive MedTech Growth Play

HeartFlow delivered a convincing Q2 with 48% sales growth and gross margins rising to 83%, driving strong market optimism. The company raised full-year revenue guidance to $246–$250 million, though the outlook appears conservative given recent momentum and sequential growth. Shares now trade at 13x sales, supported by accelerating topline growth, expanding plaque-related revenue, and commercial adoption of its non-invasive cardiac solution.

Seeking Alpha • Aug 16, 2026

HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance

HeartFlow Inc. (NASDAQ:HTFL) shares are trading sharply higher Friday afternoon after the company reported better-than-expected second-quarter adjusted EPS results and raised its full-year financial outlook.

Benzinga • Aug 14, 2026